Department of Psychological Sciences, University of Connecticut, Storrs, Connecticut (J.D.S., S.F., J.-H.Y., R.A.R., R.E.P.); and Area de Psicobiologia, Universitat de Jaume I, Castelló, Spain (M.C.)
Department of Psychological Sciences, University of Connecticut, Storrs, Connecticut (J.D.S., S.F., J.-H.Y., R.A.R., R.E.P.); and Area de Psicobiologia, Universitat de Jaume I, Castelló, Spain (M.C.).
Pharmacol Rev. 2018 Oct;70(4):747-762. doi: 10.1124/pr.117.015107.
Effort-based decision making is studied using tasks that offer choices between high-effort options leading to more highly valued reinforcers versus low-effort/low-reward options. These tasks have been used to study the involvement of neural systems, including mesolimbic dopamine and related circuits, in effort-related aspects of motivation. Moreover, such tasks are useful as animal models of some of the motivational symptoms that are seen in people with depression, schizophrenia, Parkinson's disease, and other disorders. The present review will discuss the pharmacology of effort-related decision making and will focus on the use of these tasks for the development of drug treatments for motivational dysfunction. Research has identified pharmacological conditions that can alter effort-based choice and serve as models for depression-related symptoms (e.g., the vesicular monoamine transport-2 inhibitor tetrabenazine and proinflammatory cytokines). Furthermore, tests of effort-based choice have identified compounds that are particularly useful for stimulating high-effort work output and reversing the deficits induced by tetrabenazine and cytokines. These studies indicate that drugs that act by facilitating dopamine transmission, as well as adenosine A antagonists, are relatively effective at reversing effort-related impairments. Studies of effort-based choice may lead to the identification of drug targets that could be useful for treating motivational treatments that are resistant to commonly used antidepressants such as serotonin transport inhibitors.
基于努力的决策是通过提供高努力选项与低努力/低回报选项之间的选择来研究的,这些选项可以获得更高价值的强化物。这些任务被用于研究神经系统的参与,包括中脑边缘多巴胺和相关回路,在与动机相关的努力方面。此外,这些任务作为某些与抑郁、精神分裂症、帕金森病和其他疾病相关的动机症状的动物模型非常有用。本综述将讨论与努力相关的决策的药理学,并将重点讨论这些任务在开发治疗动机功能障碍的药物治疗中的应用。研究已经确定了可以改变基于努力的选择的药理学条件,并可作为与抑郁相关症状的模型(例如,囊泡单胺转运蛋白 2 抑制剂四苯嗪和促炎细胞因子)。此外,基于努力的选择测试已经确定了一些化合物,这些化合物特别有助于刺激高努力工作输出,并逆转四苯嗪和细胞因子引起的缺陷。这些研究表明,通过促进多巴胺传递的药物以及腺苷 A 拮抗剂,在逆转与努力相关的损伤方面相对有效。基于努力的选择研究可能会导致发现药物靶点,这些靶点可能对治疗对常用抗抑郁药(如 5-羟色胺转运抑制剂)耐药的动机治疗有用。